Page contents Key factsDecisionRelated medicine informationKey facts Invented name Firazyr Active Substance icatibant Therapeutic area Other Decision number P/0282/2012 PIP number EMEA-000408-PIP02-12 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of ACE inhibitor-induced angioedema Route(s) of administration Subcutaneous use Contact for public enquiries Shire Orphan Therapies GmbHUnited StatesE-mail: medinfoeu-ceemea@shire.comTel. +44 (0)2196 65520Fax +1 7814822954 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 23/11/2012DecisionP/0282/2012: EMA decision of 23 November 2012 on the granting of a product-specific waiver for icatibant (Firazyr), (EMEA-000408-PIP02-12)AdoptedReference Number: EMA/739090/2012 English (EN) (90.81 KB - PDF)First published: 07/01/2013Last updated: 07/01/2013ViewRelated medicine informationFirazyrShare this page